by The global compounding pharmacy market size accounted for US$ 14.92 Bn in 2022 and is projected to reach around USD 28.19 Bn by 2032, growing at a CAGR of 6.57% from 2023 to 2032.
Key Takeaways:
- North America is expected to dominate the market during the forecast period.
- By therapeutic area, the pain management segment is expected to dominate the market over the forecast period.
- By route of administration, the oral segment is expected to hold the largest revenue share over the forecast period.
- By distribution channel, the hospital pharmacy segment is expected to dominate the market over the forecast period.
Report Summary
The global compounding pharmacy market report provides a Point-by-Point and In-Depth analysis of global market size, regional and country-level market size, market share, segmentation market growth, competitive landscape, sales analysis, opportunities analysis, strategic market growth analysis, the impact of domestic and global market key players, value chain optimization, trade regulations, recent developments, product launches, area marketplace expanding, and technological innovations.
The study offers a comprehensive analysis on diverse features, including production capacities, demand, product developments, revenue generation, and sales in the compounding pharmacy market across the globe.
A comprehensive estimate on the compounding pharmacy market has been provided through an optimistic scenario as well as a conservative scenario, taking into account the sales of compounding pharmacy during the forecast period. Price point comparison by region with global average price is also considered in the study.
Download Access to a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/3185
Compounding Pharmacy Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 15.9 Billion |
| Market Size by 2032 | USD 28.19 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 6.57% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 To 2032 |
| Segments Covered | By Therapeutic Area, By Route of Administration, By Application, By Compounding Type, By Sterility, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Key Highlights:
Reports Coverage: It incorporates key market sections, key makers secured, the extent of items offered in the years considered, worldwide containerized compounding pharmacy market and study goals. Moreover, it contacts the division study gave in the report based on the sort of item and applications.
Market Outline: This area stresses the key investigations, market development rate, serious scene, market drivers, patterns, and issues notwithstanding the naturally visible pointers.
Market Production by Region: The report conveys information identified with import and fare, income, creation, and key players of every single local market contemplated are canvassed right now.
Also Read: Grow Lights Market Size To Cross USD 24.44 Bn By 2032
Compounding Pharmacy Market Players
The report includes the profiles of key compounding pharmacy market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information, key development in past five years.
Major companies operating in this area
- Fresenius Kabi
- Fagron NV
- B. Braun Medical Inc.
- Rx3 Compounding Pharmacy
- Clinigen Group PLC
- Dougherty’s Pharmacy, Inc.
- Lorraine’s Pharmacy
- Wedgewood Pharmacy
- Institutional Pharmacy Solutions
- Mcguff compounding pharmacy services
Market Segmentation
By Therapeutic Area
- Pain Management
- Hormone Replacement
- Dermal Disorders
- Nutritional Supplements
- Others
By Route of Administration
- Oral
- Topical
- Parenteral
- Others
By Application
- Pediatric
- Geriatric
- Adult
- Veterinary
By Compounding Type
- Pharmaceutical Dosage Alteration (PDA)
- Pharmaceutical Ingredient Alteration (PIA)
- Currently Unavailable Pharmaceutical Manufacturing (CUPM)
- Others
By Sterility
- Sterile
- Non-sterile
By Distribution Channel
- Compounding Pharmacy
- Hospital Pharmacy
- Others
Regional Segmentation
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Southeast Asia and Rest of APAC)
- Latin America (Brazil and Rest of Latin America)
- Middle East and Africa (GCC, North Africa, South Africa, Rest of MEA)
Research Methodology
Secondary Research
It involves company databases such as Hoover’s: This assists us to recognize financial information, the structure of the market participants and industry’s competitive landscape.
The secondary research sources referred in the process are as follows:
- Governmental bodies, and organizations creating economic policies
- National and international social welfare institutions
- Company websites, financial reports and SEC filings, broker and investor reports
- Related patent and regulatory databases
- Statistical databases and market reports
- Corporate Presentations, news, press release, and specification sheet of Manufacturers
Primary Research
Primary research includes face-to-face interviews, online surveys, and telephonic interviews.
- Means of primary research: Email interactions, telephonic discussions and Questionnaire-based research etc.
- In order to validate our research findings and analysis, we conduct primary interviews of key industry participants. Insights from primary respondents help in validating the secondary research findings. It also develops Research Team’s expertise and market understanding.
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Compounding Pharmacy Market
5.1. COVID-19 Landscape: Compounding Pharmacy Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Compounding Pharmacy Market, By Therapeutic Area
8.1. Compounding Pharmacy Market, by Therapeutic Area, 2023-2032
8.1.1. Pain Management
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Hormone Replacement
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Dermal Disorders
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Nutritional Supplements
8.1.4.1. Market Revenue and Forecast (2020-2032)
8.1.5. Others
8.1.5.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Compounding Pharmacy Market, By Route of Administration
9.1. Compounding Pharmacy Market, by Route of Administration, 2023-2032
9.1.1. Oral
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Topical
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Parenteral
9.1.3.1. Market Revenue and Forecast (2020-2032)
9.1.4. Others
9.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Compounding Pharmacy Market, By Application
10.1. Compounding Pharmacy Market, by Application, 2023-2032
10.1.1. Pediatric
10.1.1.1. Market Revenue and Forecast (2020-2032)
10.1.2. Geriatric
10.1.2.1. Market Revenue and Forecast (2020-2032)
10.1.3. Adult
10.1.3.1. Market Revenue and Forecast (2020-2032)
10.1.4. Veterinary
10.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 11. Global Compounding Pharmacy Market, By Compounding Type
11.1. Compounding Pharmacy Market, by Compounding Type, 2023-2032
11.1.1. Pharmaceutical Dosage Alteration (PDA)
11.1.1.1. Market Revenue and Forecast (2020-2032)
11.1.2. Pharmaceutical Ingredient Alteration (PIA)
11.1.2.1. Market Revenue and Forecast (2020-2032)
11.1.3. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
11.1.3.1. Market Revenue and Forecast (2020-2032)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 12. Global Compounding Pharmacy Market, By Sterility
12.1. Compounding Pharmacy Market, by Sterility, 2023-2032
12.1.1. Sterile
12.1.1.1. Market Revenue and Forecast (2020-2032)
12.1.2. Non-sterile
12.1.2.1. Market Revenue and Forecast (2020-2032)
Chapter 13. Global Compounding Pharmacy Market, By Distribution Channel
13.1. Compounding Pharmacy Market, by Distribution Channel, 2023-2032
13.1.1. Compounding Pharmacy
13.1.1.1. Market Revenue and Forecast (2020-2032)
13.1.2. Hospital Pharmacy
13.1.2.1. Market Revenue and Forecast (2020-2032)
13.1.3. Others
13.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 14. Global Compounding Pharmacy Market, Regional Estimates and Trend Forecast
14.1. North America
14.1.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.1.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.1.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.1.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.1.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.1.11. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.8.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.8.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.9. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.10. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.10.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.11.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.11.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.12. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.13. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.14. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.15.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.15.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.15.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.16. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.16.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.2.17.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.2.17.3. Market Revenue and Forecast, by Application (2020-2032)
14.2.17.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.2.18. Market Revenue and Forecast, by Sterility (2020-2032)
14.2.18.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.11.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.12.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.12.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.12.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.12.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.12.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.3.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.3.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.3.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.3.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.3.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.9. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.10.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.10.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.10.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.11. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.12. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.13.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.13.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.13.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.13.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.13.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.4.14.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.4.14.3. Market Revenue and Forecast, by Application (2020-2032)
14.4.14.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.4.14.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.4.14.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.7.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.7.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.7.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.8. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.8.1. Market Revenue and Forecast, by Distribution Channel (2020-2032)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Therapeutic Area (2020-2032)
14.5.9.2. Market Revenue and Forecast, by Route of Administration (2020-2032)
14.5.9.3. Market Revenue and Forecast, by Application (2020-2032)
14.5.9.4. Market Revenue and Forecast, by Compounding Type (2020-2032)
14.5.9.5. Market Revenue and Forecast, by Sterility (2020-2032)
14.5.9.6. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 15. Company Profiles
15.1. Fresenius Kabi
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Fagron NV
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. B. Braun Medical Inc.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. Rx3 Compounding Pharmacy
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Clinigen Group PLC
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Dougherty’s Pharmacy, Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Lorraine’s Pharmacy
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Wedgewood Pharmacy
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. Institutional Pharmacy Solutions
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Mcguff compounding pharmacy services
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
Chapter 16. Research Methodology
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
Chapter 17. Appendix
17.1. About Us
17.2. Glossary of Terms
Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
